ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Janeiro 2024 - 6:30PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the compensation committee of the Company’s
Board of Directors (the “Compensation Committee”) approved,
effective as of December 29, 2023, the grant of restricted stock
units (“RSUs”) covering 167,159 shares of ImmunoGen’s common stock
under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as
amended (the “Inducement Plan”) to six new employees.
The Inducement Plan is used exclusively for the grant of equity
awards to individuals who were not previously employees of
ImmunoGen (or following a bona fide period of non-employment), as
an inducement material to such individual’s entering into
employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the
Nasdaq Listing Rules.
Each RSU will vest as to 25% of the shares underlying the RSU
award on the first anniversary of the grant date and as to an
additional 25% of the shares underlying the RSU award annually
thereafter for the next three years, subject to the employee’s
continued employment on each vesting date. Each RSU is subject to
the terms and conditions of the Inducement Plan and the terms and
conditions of an RSU agreement covering the grants.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates to improve outcomes for
cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240102637834/en/
INVESTOR RELATIONS CONTACT ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com
MEDIA CONTACTS ImmunoGen Courtney O’Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024